Lund, Sweden, 08.00 CET, 20 February 2019 – BONESUPPORT HOLDING AB (publ) -listed on Nasdaq Stockholm – an emerging leader in Orthobiologics for the management of bone voids, invites to a conference call at 10.00 am on 27 February in connection of the Full Year Report 2018, which is published the same day at 08.00 am.
The financial report for the fourth quarter will be hosted by CEO Emil Billbäck and CFO Håkan Johansson. The presentation will be in English and can be followed via web or by telephone with the opportunity to ask questions following the presentation.
The dial-in numbers for the conference call are:
The presentation will be webcasted and can be accessed from the following web address:
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
+46 (0)708 76 87 87
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 129 million in 2017. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks.